At the crossroads of consumer fear and medical authority, there is a land ripe with opportunities for specialty practitioners and the drug companies that love them. “Prediabetes” is a mischievous little diagnosis that remains unrecognized by most international diabetes organizations, but in the United States the number of people with the diagnosis grows at a rate similar to the growth of the bank accounts of the American Diabetes Association’s resident experts. This Science article provides the minimum-effective dose of rage against the medical-pharmaceutical complex.
About the Author
Charles Piller is an investigative journalist for Science. He’s also written about public health for STAT, the Los Angeles Times and The Sacramento Bee.
Instant access to over 22,000 book summaries
Discover your next favorite book with getAbstract.
See prices >>
Stay up-to-date with emerging trends in less time.
Learn more >>